Unilever has reached a definitive agreement to acquire Grüns, a high-growth Vitamin, Mineral, and Supplement (VMS) company specializing in the U.S. greens supplement market. Announced on April 9, 2026, the transaction represents a strategic pivot for Unilever as it continues to optimize its global portfolio toward premium, high-growth categories, with a particular emphasis on its Beauty & Wellbeing division.
Founded in 2023 by Chad Janis, Grüns was established to address the challenge of consumer adherence in the nutritional supplement industry. By focusing on creating nutrient-dense products that prioritize taste and user experience, the brand has rapidly ascended to a leadership position within its category. Its success is attributed to a digitally native, culture-driven brand strategy that has resonated deeply with American consumers seeking manageable wellness rituals.
Jostein Solheim, CEO of Unilever Wellbeing, highlighted the acquisition as a major milestone for the company’s health-focused ambitions. Solheim noted that the efficacy and science-backed nature of the Grüns portfolio, combined with high levels of consumer trust and consistent usage, make it a powerful addition to Unilever’s existing wellbeing ecosystem. The partnership is expected to provide Grüns with the necessary infrastructure and global reach to scale significantly beyond its current market share.
For Grüns, the partnership marks a new chapter of accelerated growth. Founder Chad Janis indicated that the support of a global powerhouse like Unilever will allow the brand to innovate faster and reach a wider demographic. Currently distributed through both direct-to-consumer and traditional retail channels in the United States, Grüns will remain focused on its mission of simplifying daily nutrition. While the specific financial terms of the deal were not disclosed, the transaction is expected to finalize later this year, pending customary regulatory approvals and standard closing conditions.
This acquisition further expands Unilever’s presence in the high-growth wellness sector, echoing the strategic shifts detailed in the Unilever-McCormick $44 Bn Deal: Antitrust and Financial Analysis.
